Edition:
United Kingdom

Denali & Sanofi To Jointly Develop RIPK1 Inhibitors


Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES BROAD COLLABORATION WITH SANOFI TO DEVELOP RIPK1 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND INFLAMMATORY DISEASES.TO RECEIVE $125 MILLION UPFRONT PAYMENT AND FUTURE MILESTONE PAYMENTS THAT COULD EXCEED $1 BILLION.DENALI - PLAN TO JOINTLY DEVELOP,COMMERCIALIZE PROGRAMS FOR NEUROLOGICAL INDICATIONS;SANOFI WILL DO THE SAME FOR SYSTEMIC INFLAMMATORY INDICATIONS.TWO LEAD MOLECULES DNL747 AND DNL758 TARGET A CRITICAL SIGNALING IN TNF RECEPTOR PATHWAY.DENALI - WILL SHARE PROFITS FROM DNL747 IN U.S., CHINA EQUALLY;WILL RECEIVE ROYALTY FROM SANOFI FOR OTHER TERRITORIES FOR DNL747, WORLDWIDE FOR DNL758.PHASE 3 TRIALS FOR ALL NEUROLOGICAL INDICATIONS WILL BE JOINTLY FUNDED BY SANOFI (70%) AND DENALI (30%).SANOFI WILL FULLY FUND CLINICAL DEVELOPMENT COSTS FOR DNL758 IN SYSTEMIC INFLAMMATORY DISEASES.. 

Company Quote

25.17
-1.03 -3.93%
18 Apr 2019